Central noradrenaline transporter availability in highly obese, non-depressed 
individuals

Hesse, Swen; Becker, Georg-Alexander; Rullmann, Michael; Bresch, Anke; Luthardt, Julia; Hankir, Mohammed K.; Zientek, Franziska; Reißig, Georg; Patt, Marianne; Arelin, Katrin; Lobsien, Donald; Müller, Ulrich; Baldofski, S.; Meyer, Philipp M.; Blüher, Matthias; Fasshauer, Mathias; Fenske, Wiebke K.; Stumvoll, Michael; Hilbert, Anja; Ding, Yu-Shin; Sabri, Osama

doi:10.1007/s00259-016-3590-3

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_2391813_7

DetailsSummary

Released

Journal Article

Central noradrenaline transporter availability in highly obese, non-depressed individuals

MPS-Authors

/persons/resource/persons138163

Rullmann, Michael
Department of Nuclear Medicine, University of Leipzig, Germany;
Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Germany;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;

/persons/resource/persons19531

Arelin, Katrin
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Clinic for Cognitive Neurology, University of Leipzig, Germany;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Hesse, S., Becker, G.-A., Rullmann, M., Bresch, A., Luthardt, J., Hankir, M. K., et al. (2017). Central noradrenaline transporter availability in highly obese, non-depressed individuals. European Journal of Nuclear Medicine and Molecular Imaging, 44(6), 1056-1064. doi:10.1007/s00259-016-3590-3.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-5BCA-5

Abstract

Purpose

The brain noradrenaline (NA) system plays an important role in the central nervous control of energy balance and is thus implicated in the pathogenesis of obesity. The specific processes modulated by this neurotransmitter which lead to obesity and overeating are still a matter of debate.
Methods

We tested the hypothesis that in vivo NA transporter (NAT) availability is changed in obesity by using positron emission tomography (PET) and S,S-[11C]O-methylreboxetine (MRB) in twenty subjects comprising ten highly obese (body mass index BMI > 35 kg/m2), metabolically healthy, non-depressed individuals and ten non-obese (BMI < 30 kg/m2) healthy controls.
Results

Overall, we found no significant differences in binding potential (BPND) values between obese and non-obese individuals in the investigated brain regions, including the NAT-rich thalamus (0.40 ± 0.14 vs. 0.41 ± 0.18; p = 0.84) though additional discriminant analysis correctly identified individual group affiliation based on regional BPND in all but one (control) case. Furthermore, inter-regional correlation analyses indicated different BPND patterns between both groups but this did not survive testing for multiple comparions.
Conclusions

Our data do not find an overall involvement of NAT changes in human obesity. However, preliminary secondary findings of distinct regional and associative patterns warrant further investigation.